Major Changes in Voting Rights - Brunnur Vaxtarsjóður slhf has distributed its shares in Oculis Holding AG to its shareholders, resulting in major changes in voting rights [1] - The notification pertains to the distribution of shares by Brunnur Vaxtarsjóður slhf, which impacts the voting rights structure [2] Corporate Actions - The distribution of shares in Oculis Holding AG by Brunnur Vaxtarsjóður slhf is a significant corporate action affecting shareholder rights [1][2]

Group 1 - The news pertains to the vesting of earnout shares and the removal of restrictions on these ordinary shares [1]

Core Points - The notification pertains to a one-time equity incentive award issued to a director of the Company for independent consulting services [1] Summary by Category - **Equity Incentive Award**: A one-time equity incentive award has been granted to a director of the Company [1] - **Consulting Services**: The award is in recognition of the director's independent services as a consultant to the Company [1]

Company Overview - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company has a differentiated pipeline with multiple innovative product candidates, including OCS-01 for diabetic macular edema and post-cataract surgery inflammation, licaminlimab (OCS-02) for dry eye disease and non-infectious anterior uveitis, and OCS-05 for acute optic neuritis [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, aiming to enhance the health and quality of life for patients globally [3] Upcoming Events - Oculis management will participate in the Stifel 2024 Healthcare Conference on November 18-19, 2024, at the Lotte New York Palace Hotel [1] - CFO Sylvia Cheung will engage in a fireside chat on November 18, 2024, at 3:35 pm ET, with a live webcast available [2] - The company will also hold one-on-one meetings during the conference for interested investors [2]

Exhibit 99.1 Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents Unaudited Condensed Consolidated Interim: | Statements of Financial Position as of September 30, 2024 and December 31, 2023 | 3 | | --- | --- | | Statements of Loss for the three and nine months ended September 30, 2024 and 2023 | 4 | | Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 | 5 | | Statements of Changes in Equity for the nine months ended S ...

Oculis Holding AG (OCS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.77%. A quarter ago, it was expected that this company would post a loss of $0.43 per share when it actually produced a loss of $0.56, delivering a surprise of -30.23%.Over the last four quarters, the company has surpas ...

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into 2H 2026 ZUG, Switzerlan ...

Oculis Holding AG (OCS) shares soared 7.9% in the last trading session to close at $17.05. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 28.3% gain over the past four weeks.Earlier this month, the company announced the acceleration of patient enrollment for both the phase III DIAMOND studies evaluating OCS-01, a topical eye drop candidate for treating diabetic macular edema, and the expansion of the DIAMOND program committees w ...

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DME ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today annou ...

Company Updates - Oculis Holding AG announced that updates on the DIAMOND Phase 3 program for OCS-01, a high-concentration dexamethasone eye drop, will be presented at Innovate Retina and Eyecelerator 2024 [1] - Dr David Eichenbaum will present the OCS-01 Phase 3 DIAMOND program results at Innovate Retina, while Dr Riad Sherif will present at Eyecelerator 2024, highlighting upcoming milestones including the ACUITY Phase 2 trial results for OCS-05 [1][3] - The DIAMOND Phase 3 program includes two trials, DIAMOND-1 and DIAMOND-2, aiming to enroll 350 patients each to evaluate the efficacy and safety of OCS-01 eye drops for diabetic macular edema (DME) [2][6] Product Pipeline - OCS-01 is a novel topical eye drop leveraging Oculis' OPTIREACH® technology, designed to treat DME non-invasively, contrasting with current invasive therapies like intravitreal injections [5] - OCS-05 is an investigational neuroprotective therapy targeting acute optic neuritis (AON) and other neuro-ophthalmic diseases, with Phase 2 ACUITY trial results expected by the end of 2024 [8][10] - Oculis' pipeline also includes licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease and non-infectious anterior uveitis [13] Clinical Trials - The DIAMOND Phase 3 trials are double-masked, randomized, multi-center studies evaluating OCS-01 eye drops in DME patients, with primary endpoints focusing on visual acuity and central subfield thickness at Week 52 [6] - The Phase 2 ACUITY trial for OCS-05 is a randomized, double-blind, placebo-controlled study assessing the safety and tolerability of OCS-05 in AON patients, with potential applications in neuroprotection [10] Market and Disease Context - Diabetic macular edema (DME) affects approximately 37 million people globally, with prevalence expected to rise to 53 million by 2040 due to increasing diabetes rates [7] - Acute optic neuritis (AON) is a rare disease affecting up to 5 in 100,000 people annually, often leading to permanent visual impairment and frequently associated with multiple sclerosis [11][12] Industry Events - Innovate Retina focuses on advancements in retinal care, including diabetic retinopathy, gene therapy, and ocular imaging, while Eyecelerator highlights industry trends and innovative eye care products [4][5]